Arene C–H Functionalisation Using a Removable/Modifiable Or A

Total Page:16

File Type:pdf, Size:1020Kb

Arene C–H Functionalisation Using a Removable/Modifiable Or A Chem Soc Rev View Article Online TUTORIAL REVIEW View Journal | View Issue Arene C–H functionalisation using a removable/ modifiable or a traceless directing group strategy Cite this: Chem. Soc. Rev., 2014, 43, 6906 Fengzhi Zhang*ab and David R. Spring*b The use of coordinating moieties as directing groups for the functionalisation of aromatic carbon–hydrogen (C–H) bonds has become an efficient strategy for the selective construction of new carbon–carbon (C–C) and carbon–heteroatom (C–X) bonds in arenes. However many directing groups cannot be easily removed/ modified from the products after C–H functionalisation, thus limiting the structural diversity of the products. Received 25th April 2014 This limitation can be overcome by employing removable/modifiable or traceless directing groups which DOI: 10.1039/c4cs00137k can be easily attached to the starting materials and detached from the products. In this tutorial review, we give an overview of recent advances in this emerging field which have dramatically increased the synthetic www.rsc.org/csr applicability of C–H functionalisation processes. Key learning points (1) Traditionally inert C–H bonds can be functionalised. (2) Site-selective functionalisation of aromatic derivatives can be achieved with the assistance of directing groups. (3) Carefully designed directing groups can be readily removed or converted into other useful functional groups efficiently. (4) The functionalised aromatic compounds have use in natural product chemistry, medicinal chemistry and material chemistry. (5) The field is fast growing and has great potential to expedite the synthesis of complex molecules. 1. Introduction The direct cleavage of an unreactive C–H bond, followed by the formation of a new C–C or C–X bond at a specific site within a Scheme 1 Pd-mediated arene C–H olefination of chlorobenzene. molecule would constitute an ideal synthetic operation,1 avoiding the traditional requirement of preinstalled functional handles such as halide, triflate, boron or tin. One key limitation of this transformation is the poor regio- As early as 1968, the pioneering organometallic chemist Jack selectivity as there is little difference in reactivity between the Halpern stated that ‘‘the development of successful approaches various C–H bonds in substrates. A common strategy to address to the activation of C–H bonds remains to be achieved and this problem involves the use of substrates that contain metal- presently constitutes one of the most important and challenging coordinating functional groups, directing the metal to activate 2 problems in this whole field’’. Since then, the discovery of new proximal C–H bonds via cyclometallated intermediates. methods for C–H bond cleavage by transition-metal complexes In 1963, Kleiman and Dubeck reported the formation of an has been a long-standing goal of the synthetic community. azobenzenenickel complex 5 by treatment of azobenzene 4 with In 1967, Fujiwara reported the first olefination of benzene dicyclopentadienylnickel at 135 1C for 4 h (Scheme 2).4 The azo 3 with a styrene–palladium chloride complex. However, when functional group, working as a metal-coordinating directing mono-substituted arenes such as chlorobenzene 2 were exposed to the complex, a mixture of different isomers (3a, 3b and 3c)was obtained (Scheme 1). a College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, P. R. China 310014. E-mail: [email protected] b Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK. E-mail: [email protected] Scheme 2 First example of Ni-catalysed arene C–H bond activation. 6906 | Chem. Soc. Rev., 2014, 43, 6906--6919 This journal is © The Royal Society of Chemistry 2014 View Article Online Tutorial Review Chem Soc Rev group, brings the metal in close proximity to the ortho C–H bond An elegant report by Yu and co-workers in 2011 exemplifies to be activated, resulting in high levels of regioselectivity. After how directing group strategies can enable the diverse C–H func- reduction of the five-membered metallacycle 5 with lithium tionalisations of privileged molecular frameworks (Scheme 4).7 aluminium deuteride, the metal atom in the ortho-position of Sulfonamides are important pharmacophores found in nearly the azobenzene was replaced by deuterium to give product 6. 200 drugs currently on the market, including the non-steroidal Cyclic platinum and palladium complexes and their corre- anti-inflammatory blockbuster drug Celecoxib 7b.Oneofthe sponding deuterium substituted products were also reported. potential bottlenecks in identifying promising drug candidates is This was the first example of using a metal-coordinating the rapid access to molecular diversity. Taking advantage of the functional group to control the regioselectivity of the transition- directing ability of the sulfonamide, Yu and co-workers applied metal insertion into a C–H bond. This early report demon- their newly developed Pd(II)-catalysed C–H functionalisation reac- strates the impressive reactivity of transition-metal catalysts in tion to a broad range of C–C and C–X bond-forming processes. activating C–H bonds with the assistance of metal-coordinating Six distinct analogues (8–13) of Celecoxib 7b were prepared using directing groups, and opened the door for aromatic C–H this approach, including carboxylation, carbonylation, olefination, functionalisation through this method. Since then many examples iodination, arylation or the alkylation process. Remarkably, the of stoichiometric C–H bond cleavage by various metals were coordinating ability of the sulfonamide group was able to override discovered,1 the development of a catalytic method as a key step that of the diazine, which is itself a commonly employed hetero- towards a synthetically useful process was not realised until the cyclic directing group, affording exclusive site-selectivity in the pioneering work of Murai in 1993 on ruthenium catalysed ortho- presence of multiple potentially reactive C–H bonds. The N-aryl alkylations of aromatic ketones with olefins.5 moiety of the sulfonamide can be kept as part of the pharma- Cyclopalladation of C–H bond containing aromatic compounds cophore or readily removed by hydrolysis with TFA in order to has been extensively investigated and has been found to proceed prepare other derivatives. Two years later, Yu and Baran success- along different pathways (Scheme 3).1,6 Astronglycoordinating fully applied the same strategy for the divergent functionalisation nitrogen-containing directing group was typically required to of the core of bioactive natural product (+)-hongoquercin through promote the facile cyclopalladation, which severely limits the the use of readily removable carboxylic acid and amide directing substrate scope. Nevertheless, these studies have served as a groups.7 These two examples demonstrate the power of the pivotal platform for further discovering and optimising this directing group assisted C–H functionalisation to the late-stage unprecedented mode of catalysis. Thus interest in directing group modifying a privileged molecular framework which would have strategies for catalytic C–H bond functionalisation processes has otherwise required many steps to make prior to the development increased dramatically. of these unprecedented transformations. Various directing groups, such as heterocycles, carbonyl- related functional groups, amines and alcohols, have been employed for catalytic arene C–H bond functionalisation and can be categorised into three different approaches (Scheme 5): Approach 1: after the C–H bond functionalisation of sub- strate 14, the directing group remains part of the product 15,or undergoes further cyclisation to form a heterocycle 16. These Scheme 3 Cyclopalladation models. directing groups cannot be conveniently removed or undergo Fengzhi Zhang received his PhD David Spring is currently a (2008) from the University of Professor at the University of Nottingham (UK) under Professor Cambridge within the Chemistry Nigel Simpkins. After post-doctoral Department. He received his work with Professors John Moses DPhil (1998) from Oxford (2008–2009, Nottingham) and University under Sir Jack Mike Greaney (2009–2011, Baldwin. He then worked as a Edinburgh), he joined the Univer- Wellcome Trust Postdoctoral sity of Cambridge working with Fellow at Harvard University Professors Matthew Gaunt (2011– with Stuart Schreiber (1999– 2013) and David Spring (2013– 2001), after which he joined the 2014). He then took up a faculty faculty at the University of Cam- Fengzhi Zhang position at Zhejiang University of David R. Spring bridge. His research programme Technology (China). His research is focused on synthetic chemistry interests include the discovery of novel catalytic reactions and their and chemical biology. synthetic applications. This journal is © The Royal Society of Chemistry 2014 Chem. Soc. Rev., 2014, 43, 6906--6919 | 6907 View Article Online Chem Soc Rev Tutorial Review Scheme 4 Selective arene C–H functionalisation directed by a sulfonamide group. (Scheme 5, approach 2). We will mainly focus on the C–C and C–X bond-forming reactions based on arene substrates using traceless directing groups (Scheme 5, approach 3). 2. C–C bond formation 2.1 Arylation The biaryl motif is ubiquitous in bioactive natural products, pharmaceuticals and functional materials. While Pd-catalysed cross-couplings such as Stille and Suzuki couplings have been successfully employed for biaryl synthesis, the requirement of prefunctionalisation of
Recommended publications
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0186168 A1 Konieczka Et Al
    US 2016O1861 68A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0186168 A1 Konieczka et al. (43) Pub. Date: Jun. 30, 2016 (54) PROCESSES AND HOST CELLS FOR Related U.S. Application Data GENOME, PATHWAY. AND BIOMOLECULAR (60) Provisional application No. 61/938,933, filed on Feb. ENGINEERING 12, 2014, provisional application No. 61/935,265, - - - filed on Feb. 3, 2014, provisional application No. (71) Applicant: ENEVOLV, INC., Cambridge, MA (US) 61/883,131, filed on Sep. 26, 2013, provisional appli (72) Inventors: Jay H. Konieczka, Cambridge, MA cation No. 61/861,805, filed on Aug. 2, 2013. (US); James E. Spoonamore, Publication Classification Cambridge, MA (US); Ilan N. Wapinski, Cambridge, MA (US); (51) Int. Cl. Farren J. Isaacs, Cambridge, MA (US); CI2N 5/10 (2006.01) Gregory B. Foley, Cambridge, MA (US) CI2N 15/70 (2006.01) CI2N 5/8 (2006.01) (21) Appl. No.: 14/909, 184 (52) U.S. Cl. 1-1. CPC ............ CI2N 15/1082 (2013.01); C12N 15/81 (22) PCT Filed: Aug. 4, 2014 (2013.01); C12N 15/70 (2013.01) (86). PCT No.: PCT/US1.4/49649 (57) ABSTRACT S371 (c)(1), The present disclosure provides compositions and methods (2) Date: Feb. 1, 2016 for genomic engineering. Patent Application Publication Jun. 30, 2016 Sheet 1 of 4 US 2016/O186168 A1 Patent Application Publication Jun. 30, 2016 Sheet 2 of 4 US 2016/O186168 A1 &&&&3&&3&&**??*,º**)..,.: ××××××××××××××××××××-************************** Patent Application Publication Jun. 30, 2016 Sheet 3 of 4 US 2016/O186168 A1 No.vaegwzºkgwaewaeg Patent Application Publication Jun. 30, 2016 Sheet 4 of 4 US 2016/O186168 A1 US 2016/01 86168 A1 Jun.
    [Show full text]
  • Introduction (Pdf)
    Dictionary of Natural Products on CD-ROM This introduction screen gives access to (a) a general introduction to the scope and content of DNP on CD-ROM, followed by (b) an extensive review of the different types of natural product and the way in which they are organised and categorised in DNP. You may access the section of your choice by clicking on the appropriate line below, or you may scroll through the text forwards or backwards from any point. Introduction to the DNP database page 3 Data presentation and organisation 3 Derivatives and variants 3 Chemical names and synonyms 4 CAS Registry Numbers 6 Diagrams 7 Stereochemical conventions 7 Molecular formula and molecular weight 8 Source 9 Importance/use 9 Type of Compound 9 Physical Data 9 Hazard and toxicity information 10 Bibliographic References 11 Journal abbreviations 12 Entry under review 12 Description of Natural Product Structures 13 Aliphatic natural products 15 Semiochemicals 15 Lipids 22 Polyketides 29 Carbohydrates 35 Oxygen heterocycles 44 Simple aromatic natural products 45 Benzofuranoids 48 Benzopyranoids 49 1 Flavonoids page 51 Tannins 60 Lignans 64 Polycyclic aromatic natural products 68 Terpenoids 72 Monoterpenoids 73 Sesquiterpenoids 77 Diterpenoids 101 Sesterterpenoids 118 Triterpenoids 121 Tetraterpenoids 131 Miscellaneous terpenoids 133 Meroterpenoids 133 Steroids 135 The sterols 140 Aminoacids and peptides 148 Aminoacids 148 Peptides 150 β-Lactams 151 Glycopeptides 153 Alkaloids 154 Alkaloids derived from ornithine 154 Alkaloids derived from lysine 156 Alkaloids
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,550,489 B2 Hagmann Et Al
    US007550489B2 (12) United States Patent (10) Patent No.: US 7,550,489 B2 Hagmann et al. (45) Date of Patent: Jun. 23, 2009 (54) SUBSTITUTED PYRIDYOXY AMIDES 6,258,837 B1 7/2001 Fukami et al. O O 6,335,345 B1 1/2002 Fukami et al. (75) Inventors: William K. Hagmann, Westfield, NJ 6,344,474 B1 2/2002 Maruani et al. (US); Linus S. Lin Westfield, NJ (US); 6,344,481 B1 2/2002 Cornelius et al. Shrenik K. Shah, Metuchen, NJ (US); 6,355,631 B1 3/2002 Achard et al. Ravindra N. Guthikonda, Edison, NJ 6,359,175 B1 3/2002 Philippe et al. (US); Hongbo Qi, Edison, NJ (US); 6.479,479 B2 11/2002 Achard et al. Linda L. Chang, Wayne, NJ (US); Ping 6,509,367 B1 1/2003 Martin et al. Liu, Edison, NJ (US); Helen M. 2002fOOO6964 A1 1/2002 Young et al. Armstrong, Westfield, NJ (US); James 2002/00101.92 A1 1/2002 Coe et al. P. Jewell, Jersey City, NJ (US); Thomas 2002.0062022 A1 5, 2002 Sabb et al. J. Lanza, Jr., Edison, NJ (US) 2002/0091114 A1 7/2002 Piot-Grosjean et al. 2003.0114495 A1 6/2003 Finke et al. (73) Assignee: Merck & Co., Inc., Rahway, NJ (US) 2004/0058820 A1 3/2004 Hagmann et al. (*) Notice: Subject to any disclaimer, the term of this 2004/0122033 A1 6/2004 Nargund et al. patent is extended or adjusted under 35 2004/0248956 Al 12/2004 Hagmann et al. U.S.C. 154(b) by 0 days.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2006) (Rev
    Harmonized Tariff Schedule of the United States (2006) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7 ACRIFLAVINIUM
    [Show full text]
  • The FEMA GRAS Assessment of Cinnamyl Derivatives Used As Flavor Ingredients
    FUlIlnlllllllil>l ELSEVIER Food and Chemical Toxicology 42 (2004) 157-185 TIIIialqy www.elsevier.com/locate/foodchemtox Review The FEMA GRAS assessment of cinnamyl derivatives used as flavor ingredients Timothy B. Adamsa,*,2, Samuel M. Cohenb,l, John Daulle,3, Victor J. Ferond,l, Jay 1. Goodmane,l, Lawrence J. Marnettf,l, Ian C. Munrog,4, Philip S. Portogheseh,l, Robert L. Smithi,l, William J. WaddeW,l, Bernard M. Wagnerk,l,l "Flavor and Extract Manufacturers Association, i620 i Street, N. w., Suite 925, Washington, DC 20006, USA hDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA CDepartment ofPharmacology and Toxicology, University ofKansas Medical Center, Kansas City, Kansas, USA dTNO Nutrition & Food Research institute, Toxicology, Utrechtseweg 48, The Netherlands CDepartment of Pharmacology and Toxicology, Michigan State University, B440 Life Science Building, East Lansing, Michigan, USA fDepartment ofBiochemistry, Vanderbilt University School ofMedicine, Nashville, Tennessee, USA gCanTox, inc., Mississauga, Ontario, Canada hDepartment ofMedicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, USA iDivision of Biomedical Sciences Section ofMolecular Toxicology, imperial College School ofMedicine, South Kensington, London SW7 2AZ, UK iDepartment of Pharmacology and Toxicology, University ofLouisville School ofMedicine, Louisville, Kentucky, USA kNew York University, School of Medicine, New York, New York, USA IBernard M. Wagner, Associates, Millburn, New Jersey, USA Received 2 July 2003; received in revised form 21 August 2003; accepted 31 August 2003 Abstract This publication is the seventh in a series of safety evaluations performed by the Expert Panel of the Flavor and Extract Manu­ facturers Association (FEMA). In 1993, the Panel initiated a comprehensive program to re-evaluate the safety of more than 1700 GRAS flavoring substances under conditions of intended use.
    [Show full text]
  • Safety Evaluation of Certain Food Additives and Contaminants/ Prepared by the Sixty-first Meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA)
    WHO FOOD Safety evaluation of certain ADDITIVES food additives and SERIES: 52 contaminants Prepared by the Sixty-first meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) World Health Organization, Geneva, 2004 IPCS—International Programme on Chemical Safety WHO Library Cataloguing-in-Publication Data Safety evaluation of certain food additives and contaminants/ prepared by the sixty-first meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA). (WHO food additives series ; 52) 1. Food additives—toxicity 2. Flavoring agents—toxicity 3. Food coloring agents—toxicity 4. Food contamination 5. Risk assessment I. Joint FAO/WHO Expert Committee on Food Additives. Meeting (61st : 2003 : Rome, Italy) II. Series ISBN 92 4 166052 X (NLM classification: WA 712) ISSN 0300-0923 This publication is a contribution to the International Programme on Chemical Safety. The International Programme on Chemical Safety (IPCS), established in 1980, is a joint venture of the United Nations Environment Programme (UNEP), the International Labour Organisation (ILO), and the World Health Organization (WHO). The overall objectives of the IPCS are to establish the scientific basis for assessing the risk to human health and the environment to exposure from chemicals, through international peer-review processes as a prerequisite for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals. The Inter-Organization Programme for the Sound Management of Chemicals (IOMC) was established in 1995 by UNEP, the Food and Agriculture Organization of the United Nations, WHO, the United Nations Industrial Development Organization, and the Organisation for Economic Co-operation and Development (Participating Organizations), following recommendations made by the 1992 United Nations Conference on the Environment and Development to strengthen cooperation and increase coordination in the field of chemical safety.
    [Show full text]
  • List of European Pharmacopoeia Reference Standards
    List of European Pharmacopoeia Reference Standards Effective from 2021/9/29 Order Reference Standard Batch Quantity Sale Information Monograph Storage Shipping Shipment Price Code n° per vial Unit group with DGD Y0001552 Abacavir for peak identification CRS 1 10 mg 1 2589 +5°C+/-3°C A1A 79 € Y0001551 Abacavir for system suitability CRS 1 10 mg 1 2589 +5°C+/-3°C A1A 79 € Y0001561 Abacavir sulfate CRS 1 20 mg 1 2589 +5°C+/-3°C A1A 79 € Y0002199 Acamprosate calcium CRS 1 80 mg 1 See leaflet 1585 +5°C+/-3°C A1A 79 € Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 This reference standard was officially withdrawn from monograph 1585 L 79 € 01/2017:1585 on 01/01/2021 and replaced by Y0002199 Acamprosate calcium. The reference will however remain available for sale for a further 6 months (subject to stock availability), i.e. until 01/07/2021. The reference will remain visible in the catalogue until 01/01/2022. ; Batch 1 is valid until 1 January 2022 Y0000116 Acamprosate impurity A CRS 2 110 mg 1 3-aminopropane-1-sulfonic acid (homotaurine) 1585 +5°C+/-3°C A1A 79 € Y0000500 Acarbose CRS 3 100 mg 1 See leaflet 2089 +5°C+/-3°C A1A 79 € Y0000354 Acarbose for identification CRS 1 10 mg 1 2089 +5°C+/-3°C A1A 79 € Y0000427 Acarbose for peak identification CRS 4 20 mg 1 2089 +5°C+/-3°C A1A 79 € A0040000 Acebutolol hydrochloride CRS 1 50 mg 1 0871 +5°C+/-3°C A1A 79 € Y0000359 Acebutolol impurity B CRS 2 10 mg 1 N-[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] 0871 +5°C+/-3°C A1A 79 € propoxy]phenyl]acetamide (diacetolol) Y0000127 Acebutolol
    [Show full text]
  • Schedule Clxxiii - European Union
    SCHEDULE CLXXIII - EUROPEAN UNION PART I MOST-FAVOURED-NATION TARIFF SECTION II - Other Products PHARMA AGREEMENT (*) HEADNOTES Elimination of Duties on Pharmaceutical Products The EU has eliminated customs duties and all other duties and charges, as defined within the meaning of Article II.1 (b) of the General Agreement, on all items in the following categories: (i) items classified (or classifiable) in Harmonised System Chapter 30; (ii) items classified (or classifiable) in HS headings 2936, 2937, 2939 and 2941, with the exception of dihydrostreptomycin and salts, esters, and hydrates thereof; (iii) pharmaceutical active ingredients listed in Section IIC that bear an "international non-proprietary name" (INN) from the World Health Organisation; (iv) salts, esters and hydrates of pharmaceutical products which are described by the combination of an INN active ingredient contained in Section IIC with a prefix or suffix as designated in Section IID, as long as such salts, ester or hydrate is classified in the same HS 6-digit heading as the INN active ingredient; (v) salts, esters and hydrates of INN active ingredients that are separately contained in Section IIE and that are not classified in the same HS 6-digit heading as the INN active ingredient; (vi) additional products used for the production and manufacture of finished pharmaceuticals as designated in Section IIF.
    [Show full text]
  • Pharmaceutical Impurities and Primary Reference Standards Catalogue
    ALL PRODUCTS LINK TO OUR WEBSHOP INCLUDES SINCENEW M RELE A A A LL RCH 2015SES Pharmaceutical impurities and primary reference standards Catalogue supplement 2016 detailed certificates of analysis • acknowledged by r egu lat or y au th o r it ie s w o r l d w i d e • p h a r m a c e u t i c a l i m p u r i t i e s • c u s t o m s y n t h e s i s e d i m p u ities ities r • pharmaceutical primary standards primary pharmaceutical LGC Quality - ISO 9001 • ISO/IEC 17025 • ISO Guide 34 • GMP/GLP • ISO 13485 • ISO/IEC 17043 Dear customer, Welcome to our 2016 supplement, updating our Also, we would like to take the opportunity to inform pharmaceutical impurities and primary reference you about some exciting news about our production standards catalogue which we released in early facilities in Luckenwalde, Germany: 2015. • We will open a state-of-the-art warehouse in early With this update, we provide more than 1,100 autumn which will serve as the main hub for our new reference standards for impurity and active global logistics operations pharmaceutical ingredient (API) testing to the global pharmaceutical quality control community. • During our quality audit in January 2016, we have renewed our GMP confirmation Our impurities range under the MM brand features close to 4,000 reference standards for impurity and • We have further improved our synthesis capacities APIs, suitable for almost any application in analytical for you to obtain more relevant substances in research and development, method validation and shorter time and to characterise them as important routine quality control.
    [Show full text]